ArticleWorld journal of hepatology2025
Improved clinical outcomes following embolization of extrahepatic portosystemic shunts in cirrhotic patients with recurrent hepatic encephalopathy.
Article in World journal of hepatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHepatic encephalopathy (HE) affects more than 30% of patients with cirrhosis. Extrahepatic portosystemic shunt (EHPSS) has been suggested to be a contributing factor to HE recurrence and mortality. Therefore, early detection and intervention in EHPSS may improve patient outcomes.
aimTo evaluate the effects of shunt embolization on mortality and HE recurrence.
methodsIn this retrospective case-control study, 16 cirrhotic patients with HE treated at a tertiary care center from January 2012 to August 2022 were included. Outcomes in eight patients who underwent embolization of EHPSS were compared with those in eight patients receiving standard care without embolization. Data on baseline characteristics, HE recurrence, and overall survival were collected and analyzed using Kaplan-Meier and log-rank tests.
resultsBaseline characteristics were comparable between the groups. The 1-year overall survival rate was significantly higher in the treatment group (0.50) than in the control group (0.33). The HE recurrence-free rate was also higher in the treatment group (1.00) than in the control group (0.17). The median survival duration was longer in the treatment group {not reached [95% confidence interval (CI): 23.84 to not available (NA)]} than in the control group [15.02 months (95%CI: 9.86 to NA)] (
conclusionEHPSS embolization significantly improves 1-year survival and prevents recurrence of HE in cirrhotic patients. Routine computed tomography and early embolization are clinically beneficial.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.